作為(wei)中國新藥(yao)研發創新的(de)開拓者(zhe)和引領者(zhe),藥(yao)明(ming)康(kang)德(de)于今年5月登陸A股市(shi)場。頂著醫藥(yao)獨(du)角(jiao)獸的(de)光環,藥(yao)明(ming)康(kang)德(de)自上市(shi)以來一直廣泛市(shi)場關(guan)注。截至(zhi)8月21日(ri)收盤,公司股價報收于79.3元/股,市(shi)值超800億元。
8月(yue)21日晚間,藥明康(kang)德披露(lu)了(le)其上市后(hou)首份半年度報(bao)告(gao)。報(bao)告(gao)顯(xian)示,今年1月(yue)份至6月(yue)份,公司實現營業收入44.09億元(yuan),歸屬于上市公司股東的凈利潤12.72億元(yuan),分別同比(bi)增長20.29%、71.31%。
二季度業績反轉
扣非后凈利環比增一倍
作為最全(quan)面(mian)和最具研(yan)發(fa)實力的小分子(zi)化學(xue)藥物(wu)發(fa)現、研(yan)發(fa)及(ji)(ji)開發(fa)一體(ti)化服(fu)務平臺,公司通(tong)過全(quan)球26個研(yan)發(fa)基地/分支機(ji)構(gou)為超過3000家客(ke)戶提供小分子(zi)化學(xue)藥的發(fa)現、研(yan)發(fa)及(ji)(ji)生(sheng)產的全(quan)方位、一體(ti)化平臺服(fu)務,以全(quan)產業鏈平臺的形式面(mian)向全(quan)球制藥企業提供各類新藥的研(yan)發(fa)、生(sheng)產及(ji)(ji)配套服(fu)務,并開展部(bu)分醫(yi)療(liao)器械檢(jian)測及(ji)(ji)精(jing)準醫(yi)療(liao)研(yan)發(fa)生(sheng)產服(fu)務。
報(bao)告顯示(shi),上(shang)半年公司主(zhu)營(ying)業務穩定(ding)增長(chang),盈利能力相應提高,相較一季(ji)度公司歸屬(shu)于發(fa)行人股東的扣除非經(jing)常性損益后凈利潤同比下滑8.53%的業績表(biao)現,二季(ji)度公司業績實現反轉。
記者注意到,二季度公(gong)(gong)(gong)司扣(kou)非后歸(gui)屬于(yu)上市公(gong)(gong)(gong)司股(gu)(gu)東(dong)的(de)凈利潤實現(xian)近5.63億元,環比(bi)一季度增長(chang)超(chao)一倍,上半年公(gong)(gong)(gong)司整體(ti)歸(gui)屬于(yu)上市公(gong)(gong)(gong)司股(gu)(gu)東(dong)的(de)扣(kou)除非經常性(xing)損(sun)益的(de)凈利潤為8.27億元,同比(bi)增長(chang)32.3%。
據半年(nian)度報告,今年(nian)上半年(nian)藥(yao)明康德(de)現有四(si)大業(ye)務(wu)板(ban)塊(kuai),中國區實(shi)驗室(shi)服(fu)務(wu)實(shi)現營收(shou)(shou)24.16億元,臨床研究及其(qi)他(ta)CRO服(fu)務(wu)實(shi)現營收(shou)(shou)2.31億元,CMO/CDMO業(ye)務(wu)實(shi)現營收(shou)(shou)12.09億元,分別同(tong)比(bi)(bi)增長(chang)21.65%、58.8%、26.8%。公司(si)美國區實(shi)驗室(shi)服(fu)務(wu)實(shi)現營收(shou)(shou)5.46億元,同(tong)比(bi)(bi)下降1.93%。
四(si)大(da)業(ye)(ye)務(wu)(wu)板塊(kuai)毛(mao)(mao)(mao)利(li)(li)方面(mian),中國(guo)區實(shi)驗室(shi)服(fu)務(wu)(wu)毛(mao)(mao)(mao)利(li)(li)實(shi)現(xian)(xian)10.9億元(yuan),公(gong)(gong)司(si)臨床研究及其他CRO服(fu)務(wu)(wu)實(shi)現(xian)(xian)毛(mao)(mao)(mao)利(li)(li)5641.47萬(wan)元(yuan),公(gong)(gong)司(si)CMO/CDMO業(ye)(ye)務(wu)(wu)實(shi)現(xian)(xian)毛(mao)(mao)(mao)利(li)(li)4.93億元(yuan),分別同(tong)比(bi)增(zeng)長17.97%、35.52%、12.94%,美國(guo)區實(shi)驗室(shi)服(fu)務(wu)(wu)實(shi)現(xian)(xian)毛(mao)(mao)(mao)利(li)(li)1.25億元(yuan),同(tong)比(bi)下降29.49%。上(shang)半年(nian),公(gong)(gong)司(si)實(shi)現(xian)(xian)綜合毛(mao)(mao)(mao)利(li)(li)17.67億元(yuan),較2017年(nian)同(tong)期(qi)(qi)(qi)增(zeng)長11.08%。公(gong)(gong)司(si)方面(mian)表(biao)示,2018年(nian)上(shang)半年(nian)人(ren)民幣平均匯率較去年(nian)同(tong)期(qi)(qi)(qi)升值給公(gong)(gong)司(si)盈利(li)(li)造成較大(da)影(ying)響,如以(yi)去年(nian)同(tong)期(qi)(qi)(qi)平均匯率來測算,主營業(ye)(ye)務(wu)(wu)毛(mao)(mao)(mao)利(li)(li)同(tong)比(bi)增(zeng)長25.14%。
記者注(zhu)意到,公(gong)司(si)(si)主(zhu)營業務在(zai)保持(chi)穩定增長的(de)同時,作為(wei)金融資(zi)產計量的(de)被投資(zi)公(gong)司(si)(si)的(de)公(gong)允(yun)價(jia)值(zhi)增加較多,在(zai)適(shi)用《企業會計準則(ze)第22號—金融工(gong)具(ju)確認(ren)和計量》等一系列(lie)金融工(gong)具(ju)相關會計準則(ze)后(hou),上述(shu)公(gong)允(yun)價(jia)值(zhi)變動(dong)中歸屬于當期的(de)部分4.32億元計入(ru)本期損益,增厚了公(gong)司(si)(si)整(zheng)體業績,上半年藥明康德(de)歸屬于上市公(gong)司(si)(si)股東的(de)凈利潤同比增長71.31%。
研發支出1.78億元
同比增長53.75%
據(ju)悉(xi),目前,全球制藥研(yan)(yan)發(fa)(fa)服(fu)務市場競爭日趨激烈。藥明(ming)康德(de)在(zai)(zai)特定的(de)(de)(de)服(fu)務領域(yu)面(mian)臨(lin)的(de)(de)(de)競爭對手主要包括(kuo)各(ge)類專業(ye)CRO/CMO/CDMO機構(gou)(gou)或(huo)大型(xing)藥企自身的(de)(de)(de)研(yan)(yan)發(fa)(fa)部門,其中(zhong)多數為國(guo)際化大型(xing)藥企或(huo)研(yan)(yan)發(fa)(fa)機構(gou)(gou),這些企業(ye)或(huo)機構(gou)(gou)相比公司(si)(si)具備更(geng)強的(de)(de)(de)財力、技術能力、客戶覆蓋度。除了(le)上述成熟的(de)(de)(de)競爭對手以(yi)外(wai),公司(si)(si)還面(mian)臨(lin)來自市場新入者的(de)(de)(de)競爭,他們或(huo)擁(yong)有(you)(you)更(geng)雄厚(hou)的(de)(de)(de)資(zi)金實力,或(huo)擁(yong)有(you)(you)更(geng)有(you)(you)效(xiao)的(de)(de)(de)商業(ye)渠(qu)道,或(huo)在(zai)(zai)細分(fen)領域(yu)擁(yong)有(you)(you)更(geng)強的(de)(de)(de)研(yan)(yan)究實力。
報告(gao)期(qi)內,公(gong)(gong)司繼(ji)續強化(hua)自身(shen)綜合研發(fa)技術優勢及(ji)各項商(shang)業競爭優勢。數(shu)據顯示(shi),上(shang)半(ban)年公(gong)(gong)司擴(kuo)大經營規(gui)模,增(zeng)加了銷(xiao)售(shou)人員,銷(xiao)售(shou)費用同比去年同期(qi)增(zeng)長(chang)14.88%。與此同時,公(gong)(gong)司營業成本(ben)達26.43億元,同比增(zeng)長(chang)27.35%。對于營業成本(ben)變動的(de)原因,公(gong)(gong)司方面表(biao)示(shi),主要是由于公(gong)(gong)司繼(ji)續夯實平臺能(neng)力,加強產能(neng)及(ji)新能(neng)力建設,總部(bu)基地及(ji)藥物檢測服務研發(fa)中心項目(mu)于2018年上(shang)半(ban)年投入運營,美國細胞治療商(shang)業化(hua)生產工(gong)廠(chang)建設項目(mu)持續進行,成本(ben)上(shang)升較快。
研發能力方面,報告期內,公司重(zhong)點投入(ru)DNA編碼化合物庫建設(she)項目及(ji)其他提高服(fu)務效(xiao)率的(de)研發活動,研發支(zhi)出(chu)近1.78億(yi)元(yuan),較上年同期增長53.75%。
記者注(zhu)意(yi)到,除研(yan)發(fa)投入外,公(gong)(gong)司(si)(si)在研(yan)發(fa)方(fang)(fang)面(mian)的(de)(de)(de)(de)重視(shi)還體現在人才(cai)培養及(ji)激(ji)勵(li)(li)方(fang)(fang)面(mian)。今年8月(yue)7日,公(gong)(gong)司(si)(si)推出大范(fan)圍股(gu)權(quan)激(ji)勵(li)(li)計(ji)劃廣泛聚賢,本(ben)次激(ji)勵(li)(li)對象共(gong)計(ji)1528人。財通證券行業研(yan)究員(yuan)對此表示,限制性(xing)股(gu)權(quan)激(ji)勵(li)(li),促進公(gong)(gong)司(si)(si)長(chang)期健(jian)康(kang)發(fa)展,本(ben)次較(jiao)大范(fan)圍地對公(gong)(gong)司(si)(si)核心人員(yuan)的(de)(de)(de)(de)股(gu)票(piao)以(yi)及(ji)股(gu)票(piao)期權(quan)的(de)(de)(de)(de)激(ji)勵(li)(li),能(neng)夠(gou)(gou)充(chong)分(fen)調(diao)動公(gong)(gong)司(si)(si)核心人員(yuan)的(de)(de)(de)(de)積極性(xing),加強公(gong)(gong)司(si)(si)基層(ceng)(ceng)、中(zhong)層(ceng)(ceng)的(de)(de)(de)(de)凝聚力,進一(yi)步捆(kun)綁了(le)公(gong)(gong)司(si)(si)管(guan)理層(ceng)(ceng)和(he)股(gu)東層(ceng)(ceng)面(mian)的(de)(de)(de)(de)利益聯系,吸引(yin)和(he)留住(zhu)優秀人才(cai),促使(shi)各(ge)方(fang)(fang)能(neng)夠(gou)(gou)共(gong)同關注(zhu)公(gong)(gong)司(si)(si)的(de)(de)(de)(de)長(chang)遠健(jian)康(kang)發(fa)展。
中(zhong)(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)聲明(ming)(ming):凡本(ben)網(wang)(wang)注明(ming)(ming)“來(lai)源:中(zhong)(zhong)(zhong)(zhong)(zhong)國(guo)(guo)(guo)證(zheng)(zheng)券(quan)報(bao)(bao)·中(zhong)(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)”的所有作(zuo)(zuo)品,版(ban)權(quan)均屬于中(zhong)(zhong)(zhong)(zhong)(zhong)國(guo)(guo)(guo)證(zheng)(zheng)券(quan)報(bao)(bao)、中(zhong)(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)。中(zhong)(zhong)(zhong)(zhong)(zhong)國(guo)(guo)(guo)證(zheng)(zheng)券(quan)報(bao)(bao)·中(zhong)(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)與作(zuo)(zuo)品作(zuo)(zuo)者聯合(he)聲明(ming)(ming),任何組織未經中(zhong)(zhong)(zhong)(zhong)(zhong)國(guo)(guo)(guo)證(zheng)(zheng)券(quan)報(bao)(bao)、中(zhong)(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)以(yi)及作(zuo)(zuo)者書面授權(quan)不得(de)轉載(zai)(zai)、摘編或利用(yong)其(qi)它方式使用(yong)上述作(zuo)(zuo)品。凡本(ben)網(wang)(wang)注明(ming)(ming)來(lai)源非(fei)中(zhong)(zhong)(zhong)(zhong)(zhong)國(guo)(guo)(guo)證(zheng)(zheng)券(quan)報(bao)(bao)·中(zhong)(zhong)(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)的作(zuo)(zuo)品,均轉載(zai)(zai)自(zi)其(qi)它媒體,轉載(zai)(zai)目的在于更(geng)好(hao)服務(wu)讀者、傳遞信息之需(xu),并不代表本(ben)網(wang)(wang)贊(zan)同其(qi)觀點,本(ben)網(wang)(wang)亦不對(dui)其(qi)真(zhen)實性負責,持(chi)異議者應與原出處單位主張權(quan)利。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2020 China Securities Journal. All Rights Reserved
中國證券報社版權所有,未經書面授權不得復制或建(jian)立(li)鏡像(xiang)
經營許(xu)可(ke)證編號(hao):京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved